

Table SII. Impact of clinical condition of childhood vitiligo on the parents

Items	Sex		Progression			Site of involvement			Clinical type			Duration of disease		
	Male (n=31)	Female (n=44)	Progressive (n=27)	Stable (n=48)	Exposed sites (n=41)	Non-exposed sites (n=34)	Localized (n=61)	Vulgaris (n=10)	Segmental (n=2)	Generalized (n=2)	< 1 year (n=47)	1-2 years (n=14)	> 2 years (n=14)	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	
B1	51.0 (8.3)	52.6 (8.3)	51.2 (7.7)	52.4 (8.7)	51.7 (9.3)	52.3 (7.1)	52.3 (8.5)	47.9 (6.1)	63.0 (4.2)	50.5 (0.7)	53.0 (9.1)	51.6 (5.6)	48.6 (7.2)	
B2	43.2 (6.3)	41.2 (6.4)	42.5 (7.2)	41.8 (5.9)	43.5 (5.3)*	40.3 (7.2)*	41.8 (6.4)	45.2 (5.5)	41.5 (4.9)	33.5 (2.1)	42.3 (6.4)	41.7 (5.7)	41.3 (7.0)	
B3	44.2 (3.9)	43.9 (4.4)	43.1 (5.0)	44.5 (3.5)	44.2 (3.8)	43.7 (4.6)	44.1 (4.2)	44.5 (2.9)	45.0 (7.1)	38.0 (2.8)	44.1 (4.3)	45.1 (2.9)	42.5 (4.6)	
BZT	138.4 (10.1)	137.7 (14.0)	136.8 (13.7)	138.6 (11.8)	137.7 (13.1)	138.3 (11.9)	138.2 (12.7)	137.6 (9.4)	149.5 (16.3)	122.0 (5.7)	139.5 (13.2)	138.4 (9.0)	132.4 (12.2)	
M1	36.2 (9.4)	33.8 (8.8)	33.8 (9.3)	35.4 (9.0)	36.0 (9.4)	33.4 (8.6)	35.2 (8.3)	35.8 (13.1)	32.5 (2.1)	21.0 (1.4)	34.5 (8.9)	33.1 (8.3)	37.7 (10.3)	
M2	41.5 (14.9)	47.0 (15.5)	43.2 (15.7)	45.6 (15.3)	45.0 (15.7)	44.4 (15.3)	46.1 (15.2)	41.0 (17.5)	37.0 (5.7)	30.0 (5.7)	45.4 (15.8)	47.6 (14.3)	39.7 (15.0)	
M3	21.2 (4.5)	21.2 (4.0)	19.8 (4.1)*	21.9 (4.1)*	21.7 (4.2)	20.5 (4.2)	21.3 (4.0)	22.2 (4.8)	16.5 (0.7)	16.5 (4.9)	20.8 (3.9)	22.3 (3.6)	21.1 (5.4)	
MZT	98.8 (21.3)	102.0 (22.6)	96.8 (21.9)	102.9 (22.0)	102.7 (21.6)	98.3 (22.5)	102.5 (20.9)	99.0 (26.9)	86.0 (7.1)	67.5 (0.7)	100.7 (22.0)	103.0 (22.7)	98.5 (22.7)	
S1	31.7 (4.8)	30.1 (4.9)	29.4 (4.7)	31.5 (4.9)	30.8 (4.8)	30.6 (5.2)	30.6 (4.6)*	33.8 (4.8)*	28.0 (9.9)*	23.0 (1.4)*	30.3 (4.8)	31.3 (4.8)	31.7 (5.5)	
S2	37.0 (8.4)	38.0 (6.5)	37.4 (7.6)	37.7 (7.2)	37.2 (7.7)	38.1 (6.8)	37.6 (7.1)	40.0 (7.7)	33.5 (12.0)	29.0 (5.7)	38.0 (6.8)	36.3 (6.6)	37.7 (9.7)	
S3	21.9 (5.1)	22.6 (4.2)	22.6 (4.0)	22.2 (4.9)	21.8 (4.3)	23.0 (4.9)	22.3 (4.6)	23.9 (4.1)	21.5 (2.1)	17.0 (5.7)	22.7 (4.3)	20.6 (4.9)	22.7 (5.1)	
SZT	90.6 (16.4)	90.7 (12.2)	89.4 (13.4)	91.4 (14.4)	89.8 (14.4)	91.7 (13.6)	90.5 (13.2)*	97.7 (13.8)*	83.0 (24.0)*	69.0 (12.7)*	91.0 (12.5)	88.2 (14.6)	92.1 (18.4)	
ZCZT	327.8 (36.7)	330.4 (34.5)	323.0 (32.2)	332.9 (36.6)	330.2 (37.7)	328.3 (32.4)	331.2 (33.0)*	334.3 (41.0)*	318.5 (14.8)*	258.5 (19.1)*	331.2 (32.8)	329.6 (35.7)	323.0 (44.0)	

\*p<0.05 sex, progression and site of involvement analysed by independent samples t-test. Clinical type and duration of disease analysed using one-way analysis of variance (ANOVA).